癌症患者质子泵抑制剂使用的研究进展

doi:10.12092/j.issn.1009-2501.2018.10.015

摘要/Abstract

摘要：

质子泵抑制剂（proton pump inhibitors, PPIs）是一类抑制胃酸分泌的药物，用于急、慢性消化系统疾病的治疗，也常用于化学药物治疗、放射性治疗、应激性溃疡和合用类固醇类药物的预防性给药。临床研究中发现，大部分的PPIs的预防性给药存在不合理现象。本文综述了癌症患者合并使用PPIs的临床实验及PPIs的不良反应，为PPIs的合理用药提供参考。

关键词: 质子泵抑制剂, 癌症, 化疗药物, 类固醇, 相互作用

Abstract:

Proton pump inhibitors (PPIs) are a class of drugs that inhibit gastric acid secretion. They are used in the treatment of acute and chronic digestive diseases. They are also commonly used in chemical therapy, radiation therapy, stress ulcers and prophylactic administration of steroids. In clinical research, it is found that most of the preventive administrations of PPIs are unreasonable. This article reviews the clinical trials and adverse reactions of PPIs in cancer patients, providing a reference for rational use of PPIs.

Key words: proton pump inhibitors, cancer, chemotherapy, steroids, drug interactions

中图分类号:

黄琼，杜洁，成舒乔，龚志成. 癌症患者质子泵抑制剂使用的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(10): 1179-1187.

HUANG Qiong, DU Jie, CHENG Shuqiao, GONG Zhicheng. Progress of proton pump inhibitors using in cancer patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1179-1187.

参考文献

［1］Lodato F, Poluzzi E, Raschi E, et al. Appropriateness of proton pump inhibitor prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy［J］. Eur J Int Med, 2016, 30: 31-36.
［2］Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications［J］. Am J Gastroenterol, 2009, 104(3): 728-738.
［3］卢宏丽, 卢宏霞. 山西省某肿瘤医院住院患者质子泵抑制剂用药分析.［J］. 中国药物与临床, 2017, 17(6): 905-906.
［4］Heidelbaugh JJ, Kim AH, Chang R, et al. Overutilization of proton-pump inhibitors: what the clinician needs to know［J］. Therap Adv Gastroenterol, 2012, 5(4): 219-232.
［5］Jacobson BC, Ferris TG, Shea TL, et al. Who is using chronic acid suppression therapy and why［J］? Am J Gastroenterol, 2003, 98(1): 51-58.
［6］Smelick GsH. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development ［J］. Mol Pharm, 2013, 11(10): 4055-4062.
［7］Sartori S, Nielsen I, Maestri A, et al. Acute gastroduodenal mucosal injury after cisplatin plus etoposide chemotherapy ［J］. Oncology, 1991, 48(5): 356-361.
［8］Gorschluter M, Schmitz V, Mey U, et al. Endoscopy in patients with acute leukaemia after intensive chemotherapy［J］. Leuk Res, 2008, 32(10): 1510-1517.
［9］Numico G, Fusco V, Franco P, et al. Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use［J］. Crit Rev Oncol Hematol, 2017, 111: 144-151.
［10］Peterson DE, Boers-Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up［J］. Ann Oncol, 2015, 26 Suppl 5: v139-v151.
［11］Mavligit GM, Faintuch J, Levin B, et al. Gastroduodenal mucosal injury during hepatic arterial infusion of chemotherapeutic agents. Lack of cytoprotection by prostaglandin E1 analogue［J］. Gastroenterology, 1987, 92(3): 566-569.
［12］Aggarwal SK, San AJ, Sokhansanj A, et al. Cisplatin-induced peptic ulcers, vagotomy, adrenal and calcium modulation［J］. Anticancer Drugs, 1994, 5(2): 177-193.
［13］Contu A, Marenco G, Pani P, et al. Preventive role of pirenzepine in gastric damage during cytostatic therapy. A controlled randomized double-blind study with placebo［J］. Minerva Dietol Gastroenterol, 1989, 35(4): 269-272.
［14］Mori K, Tominaga K, Yokoyama K, et al. Efficacy of famotidine in patients with acute gastric mucosal injury after continuous infusion of cisplatin plus vindesine［J］. J Cancer Res Clin Oncol, 1995, 121(6): 367-370.
［15］Polloni A, Marchi S, Martire A, et al. Pirenzepine versus ranitidine in gastroprotection during antiblastic chemotherapy: a double-blind study［J］. Chemioterapia, 1986, 5(6): 420-423.
［16］Sartori S, Trevisani L, Nielsen I, et al. Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebo-controlled pilot study［J］. Cancer, 1996, 78(7): 1477-1482.
［17］Sartori S, Trevisani L, Nielsen I, et al. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury［J］. J Clin Oncol, 2000, 18(3): 463-467.
［18］Steer CB, Harper PG. Gastro-oesophageal complications in patients receiving cancer therapy: the role of proton pump inhibitors［J］. Eur J Gastroenterol Hepatol, 2002, 14 Suppl 1: S17-S21.
［19］翟蒙蒙, 李志刚, 沈杰, 等. 质子泵抑制剂对进展期胃癌化疗方案临床疗效的影响［J］. 中国临床药理学与治疗学, 2017, 8(22): 933-936.
［20］Bianchi PG, Lazzaroni M, Petrillo M. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients［J］. Am J Gastroenterol, 1997, 92(4): 663-667.
［21］Geis GS, Stead H, Wallemark CB, et al. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions［J］. J Rheumatol Suppl, 1991, 28: 11-14.
［22］Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications［J］. Am J Gastroenterol, 2009, 104(3): 728-738.
［23］Borras JM, Lievens Y, Barton M, et al. How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis［J］. Radiother Oncol, 2016, 119(1): 5-11.
［24］Franco P, Zeverino M, Migliaccio F, et al. Intensity-modulated adjuvant whole breast radiation delivered with static angle tomotherapy (TomoDirect): a prospective case series［J］. J Cancer Res Clin Oncol, 2013, 139(11): 1927-1936.
［25］Filippi AR, Franco P, Ricardi U. Is clinical radiosensitivity a complex genetically controlled event?［J］ Tumori, 2006, 92(2): 87-91.
［26］Steer CB, Harper PG. Gastro-oesophageal complications in patients receiving cancer therapy: the role of proton pump inhibitors［J］. Eur J Gastroenterol Hepatol, 2002, 14 Suppl 1: S17-S21.
［27］ Berkey FJ. Managing the adverse effects of radiation therapy［J］. Am Fam Physician, 2010, 82(4): 381-388, 394.
［28］Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract［J］. Int J Radiat Oncol Biol Phys, 1995, 31(5): 1213-1236.
［29］Biju PG, Gubrij I, Garg S, et al. Radiation lethality potentiation in total body irradiated mice by a commonly prescribed proton pump inhibitor, Pantoprazole sodium［J］. Int J Radiat Biol, 2014, 90(7): 554-559.
［30］Shin JM, Sachs G. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo［J］. Biochem Pharmacol, 2004, 68(11): 2117-2127.
［31］Su Q, Wang D, Yuan B, et al. Effects of proton pump inhibitors on lung cancer precise radiotherapy-induced radiation pneumonitis［J］. Cell Biochem Biophys, 2014, 70(2): 1113-1117.
［32］Welsh C, Kasirer MY, Pan J, et al. Pantoprazole decreases gastroesophageal muscle tone in newborn rats via rho-kinase inhibition ［J］. Am J Physiol Gastrointest Liver Physiol, 2014, 307(3): G390-G396.
［33］Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study［J］. Arch Intern Med, 2007, 167(9): 950-955.
［34］Eddleston JM, Pearson RC, Holland J, et al. Prospective endoscopic study of stress erosions and ulcers in critically ill adult patients treated with either sucralfate or placebo［J］. Crit Care Med, 1994, 22(12): 1949-1954.
［35］Krag M, Perner A, Moller MH. Stress ulcer prophylaxis in the intensive care unit［J］. Curr Opin Crit Care, 2016, 22(2): 186-190.
［36］Krag M, Perner A, Wetterslev J, et al. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients［J］. Intensive Care Med, 2015, 41(5): 833-845.
［37］Plummer MP, Blaser AR, Deane AM. Stress ulceration: prevalence, pathology and association with adverse outcomes［J］. Crit Care, 2014, 18(2): 213.
［38］Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group［J］. N Engl J Med, 1994, 330(6): 377-381.
［39］Marik PE, Vasu T, Hirani A, et al. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis［J］. Crit Care Med, 2010, 38(11): 2222-2228.
［40］Buendgens L, Koch A, Tacke F. Prevention of stress-related ulcer bleeding at the intensive care unit: Risks and benefits of stress ulcer prophylaxis［J］. World J Crit Care Med, 2016, 5(1): 57-64.
［41］Alhazzani W, Alenezi F, Jaeschke RZ, et al. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis［J］. Crit Care Med, 2013, 41(3): 693-705.
［42］Maclaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit［J］. JAMA Intern Med, 2014, 174(4): 564-574.
［43］Numico G, Russi EG, Vitiello R, et al. Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: a pharmacology-guided schedule［J］. Int J Radiat Oncol Biol Phys, 2006, 66(3): 731-737.
［44］Feyer PC, Maranzano E, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009［J］. Support Care Cancer, 2011, 19 Suppl 1: S5-S14.
［45］Suzuki H, Asakawa A, Amitani H, et al. Cancer cachexia--pathophysiology and management［J］. J Gastroenterol, 2013, 48(5): 574-594.
［46］Luo JC, Chang FY, Chen TS, et al. Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy［J］. Br J Clin Pharmacol, 2009, 68(2): 252-259.
［47］Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy ［J］. J Intern Med, 1994, 236(6): 619-632.
［48］Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis［J］. BMJ Open, 2014, 4(5): e4587.
［49］Jones MG, Tsega S, Cho HJ. Inappropriate prescription of proton pump inhibitors in the setting of steroid use: a teachable moment ［J］. JAMA Intern Med, 2016, 176(5): 594-595.
［50］Martinek J, Hlavova K, Zavada F, et al. "A surviving myth"--corticosteroids are still considered ulcerogenic by a majority of physicians［J］. Scand J Gastroenterol, 2010, 45(10): 1156-1161.
［51］Guslandi M. Steroid ulcers: Any news ［J］? World J Gastrointest Pharmacol Ther, 2013, 4(3): 39-40.
［52］Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis［J］. Am J Gastroenterol, 2012, 107(7): 1011-1019.
［53］Cunningham R, Dial S. Is over-use of proton pump inhibitors fuelling the current epidemic of Clostridium difficile-associated diarrhoea ［J］? J Hosp Infect, 2008, 70(1): 1-6.
［54］Taur Y, Pamer EG. Microbiome mediation of infections in the cancer setting［J］. Genome Med, 2016, 8(1): 40.
［55］Mccaleb RV, Gandhi AS, Clark SM, et al. Clinical outcomes of acid suppressive therapy use in hematology/oncology patients at an academic medical center ［J］. Ann Pharmacother, 2016, 50(7): 541-547.
［56］Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis［J］. CMAJ, 2011, 183(3): 310-319.
［57］Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis ［J］. Gut, 2014, 63(4): 552-558.
［58］Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis［J］. Osteoporos Int, 2016, 27(1): 339-347.
［59］Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies［J］. Ren Fail, 2015, 37(7): 1237-1241.
［60］Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease［J］. JAMA Intern Med, 2016, 176(2): 238-246.
［61］Linder L, Tamboue C, Clements JN. Drug-induced vitamin B12 deficiency: a focus on proton pump inhibitors and histamine-2 antagonists ［J］. J Pharm Pract, 2017, 30(6): 639-642.
［62］Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome［J］. JAMA, 2009, 301(9): 937-944.
［63］Melloni C, Washam JB, Jones WS, et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review［J］. Circ Cardiovasc Qual Outcome, 2015, 8(1): 47-55.
［64］Kuipers EJ. Proton pump inhibitors and gastric neoplasia［J］. Gut, 2006, 55(9): 1217-1221.
［65］Cheung KS, Chan EW, Wong A, et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study［J］. Gut, 2018, 67(1): 28-35.
［66］Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions［J］. Cochrane Database Syst Rev, 2014(12): D10623.
［67］Taur Y, Pamer EG. Microbiome mediation of infections in the cancer setting［J］. Genome Med, 2016, 8(1): 40.
［68］Tran KT, Mcmenamin UC, Hicks B, et al. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies［J］. Aliment Pharmacol Ther, 2018, 48(1): 55-64.
［69］Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors［J］. Clin Pharmacokinet, 2010, 49(8): 509-533.
［70］Conde-Estevez D. Targeted cancer therapy: interactions with other medicines［J］. Clin Transl Oncol, 2017, 19(1): 21-30.
［71］Ha VH, Ngo M, Chu MP, et al. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer［J］? J Oncol Pharm Pract, 2015, 21(3): 194-200.
［72］Chu MP, Ghosh S, Chambers CR, et al. Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer［J］. Clin Lung Cancer, 2015, 16(1): 33-39.
［73］Sun J, Ilich AI, Kim CA, et al. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients ［J］. Clin Colorectal Cancer, 2016, 15(3): 257-263.

[1]	何雪茹, 李颖, 马银玲, 付裕豪, 荀雪姣, 董占军. 索拉非尼和达格列净在大鼠体中药代动力学相互作用研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 498-507.
[2]	何雪茹, 付裕豪, 荀雪姣, 崔艳军, 董占军. 尿苷二磷酸葡醛酸转移酶介导的酪氨酸激酶抑制剂药物相互作用研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 936-945.
[3]	张亮, 廖勇群, 夏秦川, 周诗侗, 李小丽. 铁死亡调控信号通路以及在相关疾病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(2): 227-234.
[4]	刘宸, 方梦蝶, 徐昊, 李超, 任娟, 左博文, 张衍梅. 苍术苷靶向癌蛋白BORIS抑制癌细胞增殖的作用区域[J]. 中国临床药理学与治疗学, 2021, 26(9): 1005-1013.
[5]	刘璐, 陈笑艳. 国产小分子化学创新药临床药物相互作用研究现状[J]. 中国临床药理学与治疗学, 2021, 26(8): 863-875.
[6]	孟强, 刘克辛. 转运体介导药物相互作用的研究现状及展望[J]. 中国临床药理学与治疗学, 2021, 26(8): 876-888.
[7]	周晗, 刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 889-913.
[8]	吴蓉蓉, 陈智强, 贾翼菲, 陈宏绮, 王盼盼, 燕茹. 靶向抑制肠道菌β-葡萄糖醛酸苷酶在肿瘤预防和治疗中的应用[J]. 中国临床药理学与治疗学, 2021, 26(8): 964-974.
[9]	马月, 范方田. 葡萄糖6磷酸脱氢酶在恶性肿瘤中的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(12): 1430-1436.
[10]	孙搏, 付淑军, 陈桂良, 李丽. 药物相互作用研究在新药研发和审评决策中的应用[J]. 中国临床药理学与治疗学, 2021, 26(10): 1095-1102.
[11]	孙仁凇, 张建斌, 房佳霓, 吕侠, 唐泽耀, 田燕. 壳聚糖纳米粒作为药物递送系统在癌症治疗中的应用[J]. 中国临床药理学与治疗学, 2021, 26(1): 65-75.
[12]	赵妙惠，周佳妮，漆勇. 桑黄多糖调控PI3K/AKT/mTOR通路抑制肝癌腹水荷瘤小鼠及对化疗的减毒增效作用[J]. 中国临床药理学与治疗学, 2020, 25(4): 401-407.
[13]	杨璐，魏滨，张利萍，毕姗姗，卢炜. 应用响应曲面模型法研究丙泊酚与瑞芬太尼的最佳配伍剂量[J]. 中国临床药理学与治疗学, 2020, 25(4): 413-420.
[14]	吴俏玉，袁洪，陆瑶. 以混合探针药的方法评价白藜芦醇对人体细胞色素酶P450活性的影响[J]. 中国临床药理学与治疗学, 2020, 25(4): 426-432.
[15]	沙碧君，周素凤，王璐，赵玉清，陈西敬，邵凤. 药物相互作用临床研究方法及进展[J]. 中国临床药理学与治疗学, 2019, 24(9): 1037-1045.